Key facts
- This page summarizes Elizabeth Trehu's Form 4 filing for Jounce Therapeutics, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2023, 19:33.
Elizabeth Trehu - 09 Jan 2023 Form 4 Insider Report for Jounce Therapeutics, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 09 Jan 2023
- Net transaction value
- -$10,316
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2023, 19:33:01 UTC
- Prior SEC filing
- 03 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Caroline Gammill, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Elizabeth Trehu filed Form 4 for Jounce Therapeutics, Inc. on 11 Jan 2023.
Change
- Previous filing in this sequence was filed on 03 Feb 2022.
- Current net transaction value: -$10,316.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JNCE
transaction
Common Stock
Sale
- Transaction value
- $4,575
- Shares
- -4,159
- Change %
- -3.7%
- Price
- $1.10
- Shares after
- 108,543
- Date
- 09 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
JNCE
transaction
Common Stock
Sale
- Transaction value
- $5,741
- Shares
- -5,126
- Change %
- -4.7%
- Price
- $1.12
- Shares after
- 103,417
- Date
- 10 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
Footnote F2
Represents the weighted average share price of an aggregate total of 4,159 shares sold in the price range of $1.03 to $1.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
Represents the weighted average share price of an aggregate total of 5,126 shares sold in the price range of $1.05 to $1.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
SEC remarks
Exhibit 24 - Power of Attorney